SRI International Announces New VP for Biotechnology Business Development, Michael Tracy

MENLO PARK, Calif. - February 15, 2002 - SRI International, a leading independent scientific research institute based in Silicon Valley, announced today that Michael Tracy, D.Phil., former vice president of its Pharmaceutical Discovery Division, has taken a new role at SRI as vice president for corporate business development in biotechnology.

In this role, Dr. Tracy will create and lead strategic initiatives in biotechnology, bioinformatics and proteomics to develop SRI's market and client opportunities in these areas. He joins SRI's new Ventures and Strategic Business Development team, which identifies and develops high-value market opportunities for clients, and creates R&D programs, licensing arrangements, and spin-off ventures to realize those opportunities.

Dr. Tracy joined SRI in 1981 and held various research and management positions before being named vice president of the Pharmaceutical Discovery Division in 1996. His broad experience in directing multiple drug discovery programs for clients in the United States, Japan and Europe includes cancer chemotherapeutics, antiviral agents and antibiotics. As vice president of the Division, Dr. Tracy oversaw multidisciplinary research teams working on the synthesis and screening of novel compounds for biotechnology and pharmaceutical companies.

Dr. Tracy has a D.Phil. in organic chemistry from the University of Oxford, England. He was a postdoctoral research fellow at the University of Alberta in Edmonton, Canada and received his B.Sc. in chemistry from the University of Durham, England.

About SRI International
Silicon Valley-based SRI International (http://www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 55 years. The nonprofit research institute performs contract research and development for government agencies, commercial businesses and private foundations. SRI is well known for its innovations in information technology, telecommunications, engineering, pharmaceuticals, chemistry, physics, and the public policy areas of education, health, and economic development. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.